Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
09:00am, Friday, 08'th May 2026
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the cla
SAN DIEGO, May 8, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between Ja
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
01:53pm, Thursday, 07'th May 2026
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading lower by 11.46% on Thursday as the company recently reported record first quarter 2026 results, which included significant revenue growth.
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and Mar
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class
DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12:08pm, Thursday, 07'th May 2026
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded c
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
11:56am, Thursday, 07'th May 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
San Francisco, California--(Newsfile Corp. - May 7, 2026) - ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acqui
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
09:55am, Thursday, 07'th May 2026
ImmunityBio (IBRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.15 per share a year ago.
IMMUNITYBIO, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs ImmunityBio, Inc. (IBRX) Investors of a Securities Fraud Lawsuit
09:06am, Thursday, 07'th May 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" o
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
09:03am, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) in
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securiti
NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securiti
